1. In Vivo
  2. >>Global Vision

China: Value-Based Procurement Reshapes Strategies Of Multinational Medtech Firms

 
• By Mainbayar Badarch

China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.  

Map of China in magnifying glass (shutterstock)
• Source: Shutterstock

Regarding the key players, with a valuation more than triple that of the following competitor, Mindray Medical is the clear market leader in the medical device market with market value of CNY326bn ($44.8bn) in 2020. Next performers are Wantai Biological (CNY86bn), Lepu Medical (CNY79bn), BGI Group (CNY75bn), New Industries (CNY75bn), Autobio Diagnostics (CNY69bn) and Jafron Biomedical (CNY59bn).

In some areas, domestic companies are markedly improving their performance across operations. China’s 134 listed medtech companies generated $44bn in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

More from In Vivo

Pharma’s Space Trails Entering Transformative Era

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Surgical Robotics CEOs Talk Metrics For Success, Valuations And Competition

 
• By Marion Webb

Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.

Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds

 
• By David Wild

Richard Wilson, SVP and primary focus lead for genetic regulation at Astellas, talks with In Vivo about the company's commitment to AAV as a gene therapy delivery vehicle, recent company investments and the regulatory environment under Trump's FDA.